Cargando…
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
In patients with type 2 diabetes, chronic kidney disease (CKD) is the most common cause of kidney failure. With its increasing prevalence and limited treatment options, CKD is a major contributor to the global burden of disease. Although recent guidelines for the control of hypertension and hypergly...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323420/ https://www.ncbi.nlm.nih.gov/pubmed/35302284 http://dx.doi.org/10.1111/dom.14696 |
_version_ | 1784756546087944192 |
---|---|
author | DeFronzo, Ralph A. Bakris, George L. |
author_facet | DeFronzo, Ralph A. Bakris, George L. |
author_sort | DeFronzo, Ralph A. |
collection | PubMed |
description | In patients with type 2 diabetes, chronic kidney disease (CKD) is the most common cause of kidney failure. With its increasing prevalence and limited treatment options, CKD is a major contributor to the global burden of disease. Although recent guidelines for the control of hypertension and hyperglycaemia, as well as the use of renin‐angiotensin system inhibitors and, more recently, sodium‐glucose co‐transporter‐2 inhibitors, have improved outcomes for patients with CKD and diabetes, there is still a high residual risk of CKD progression and adverse cardiovascular events. In this review, we discuss the recently published FIDELIO‐DKD and FIGARO‐DKD studies and FIDELITY prespecified individual patient analysis. Together, these studies have established finerenone, a novel non‐steroidal mineralocorticoid receptor antagonist, as an effective treatment for kidney and cardiovascular protection and welcome addition to the pillars of treatment to slow CKD progression in patients with type 2 diabetes. |
format | Online Article Text |
id | pubmed-9323420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-93234202022-07-30 Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes DeFronzo, Ralph A. Bakris, George L. Diabetes Obes Metab Review Articles In patients with type 2 diabetes, chronic kidney disease (CKD) is the most common cause of kidney failure. With its increasing prevalence and limited treatment options, CKD is a major contributor to the global burden of disease. Although recent guidelines for the control of hypertension and hyperglycaemia, as well as the use of renin‐angiotensin system inhibitors and, more recently, sodium‐glucose co‐transporter‐2 inhibitors, have improved outcomes for patients with CKD and diabetes, there is still a high residual risk of CKD progression and adverse cardiovascular events. In this review, we discuss the recently published FIDELIO‐DKD and FIGARO‐DKD studies and FIDELITY prespecified individual patient analysis. Together, these studies have established finerenone, a novel non‐steroidal mineralocorticoid receptor antagonist, as an effective treatment for kidney and cardiovascular protection and welcome addition to the pillars of treatment to slow CKD progression in patients with type 2 diabetes. Blackwell Publishing Ltd 2022-04-18 2022-07 /pmc/articles/PMC9323420/ /pubmed/35302284 http://dx.doi.org/10.1111/dom.14696 Text en © 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Articles DeFronzo, Ralph A. Bakris, George L. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes |
title | Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes |
title_full | Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes |
title_fullStr | Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes |
title_full_unstemmed | Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes |
title_short | Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes |
title_sort | modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323420/ https://www.ncbi.nlm.nih.gov/pubmed/35302284 http://dx.doi.org/10.1111/dom.14696 |
work_keys_str_mv | AT defronzoralpha modifyingchronickidneydiseaseprogressionwiththemineralocorticoidreceptorantagonistfinerenoneinpatientswithtype2diabetes AT bakrisgeorgel modifyingchronickidneydiseaseprogressionwiththemineralocorticoidreceptorantagonistfinerenoneinpatientswithtype2diabetes |